ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing siRNA therapeutics, priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026. AbbVie has agreed to purchase shares in a concurrent private placement for approximately $100 million, resulting in a 4.9% stake in ADARx.